Praxis Precision Medicines Inc Total Liabilities
Praxis Precision Medicines Inc total liabilities. Based on the latest financial reports, Praxis Precision Medicines Inc (PRAX) has total liabilities worth $49.06 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Praxis Precision Medicines Inc (PRAX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Praxis Precision Medicines Inc (2018–2025)
Total liabilities of Praxis Precision Medicines Inc from 2018 to 2025. This chart illustrates how Praxis Precision Medicines Inc's total liabilities have evolved over time, based on quarterly financial data. Explore Praxis Precision Medicines Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
Praxis Precision Medicines Inc Competitors by Total Liabilities
The table below lists competitors of Praxis Precision Medicines Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Full Truck Alliance Co Ltd ADR
NYSE:YMM
|
USA | $3.62 Billion |
|
Vicinity Centres
AU:VCX
|
Australia | AU$5.19 Billion |
|
The Hanover Insurance Group Inc
NYSE:THG
|
USA | $13.19 Billion |
|
Shandong Hi-speed Co Ltd
SHG:600350
|
China | CN¥107.64 Billion |
|
Itissalat Al-Maghrib (IAM) S.A
F:MSPA
|
Germany | €51.67 Billion |
|
AXIS Capital Holdings Ltd
NYSE:AXS
|
USA | $25.97 Billion |
|
Janus Henderson Group PLC
NYSE:JHG
|
USA | $2.08 Billion |
|
Simpson Manufacturing Company Inc
NYSE:SSD
|
USA | $1.03 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Praxis Precision Medicines Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Praxis Precision Medicines Inc assets under control.
Liquidity & Leverage Metrics
Praxis Precision Medicines Inc Total Liabilities Ratios Explained
Praxis Precision Medicines Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.04 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.04 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Praxis Precision Medicines Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Praxis Precision Medicines Inc (2018–2025)
The table below shows the annual total liabilities of Praxis Precision Medicines Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $59.77 Million | +58.71% |
| 2024-12-31 | $37.66 Million | +106.03% |
| 2023-12-31 | $18.28 Million | -53.16% |
| 2022-12-31 | $39.02 Million | -6.95% |
| 2021-12-31 | $41.94 Million | +166.76% |
| 2020-12-31 | $15.72 Million | +107.36% |
| 2019-12-31 | $7.58 Million | +47.29% |
| 2018-12-31 | $5.15 Million | -- |
About Praxis Precision Medicines Inc
Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. The company's platforms include Cerebrum, a small molecule platform for CNS small molecule therapies to develop orally available precision therapies; and Soli… Read more